Trellis Research Lab provides end‑to‑end services for AAV gene‑therapy development, including custom capsid and transgene design, GMP‑scale vector production, and regulatory‑compliant analytical testing. It also offers preclinical validation and training programs to equip biotech, pharmaceutical, and academic teams with the expertise needed to advance AAV programs.
Funding
Funding not disclosed
Founders
Product
Problem
Developing adeno‑associated virus (AAV) gene therapies is hindered by complex vector design, scalable manufacturing, rigorous analytical requirements, and a shortage of trained specialists, making it difficult for academic and industry teams to advance programs efficiently.
Solution
Trellis Research Lab offers an integrated platform that bridges academia and industry to accelerate AAV gene‑therapy development from concept to clinic. The lab provides expert services in vector engineering, scalable GMP‑compatible process development, high‑precision analytical testing, and preclinical validation, reducing technical risk and shortening timelines. In addition, Trellis delivers customized training programs to build the multidisciplinary skill set required for modern gene‑therapy projects. By combining deep AAV biology expertise with end‑to‑end development capabilities, Trellis enables partners to focus on therapeutic innovation while outsourcing the most demanding technical components.
Target Audience
Primary customers are biotech and pharmaceutical companies, as well as academic research groups, seeking expert support for AAV‑based gene‑therapy programs and workforce development in this field.
Features
- Custom AAV capsid and transgene cassette design leveraging recombinant AAV (rAAV) engineering and host‑cell interaction studies.
- Research‑grade vector production and GMP‑scale bioprocess development, including upstream cell‑culture optimization and downstream purification pipelines.
- Comprehensive analytical suite (digital‑droplet PCR, potency assays, purity and identity testing) compliant with regulatory expectations.
- Preclinical asset development services: biodistribution, efficacy, and safety studies in relevant animal models.
- Flexible partnership models (co‑development, technology transfer, consulting) to match project needs and risk profiles.
- Structured training and education curricula covering AAV biology, manufacturing, regulatory, and economic aspects for scientists and engineers.
- Access to a multidisciplinary team with expertise in vector biology, process engineering, and translational research.